Terms: = Lymphoma AND DDR2, NTRKR3, 4921, ENSG00000162733, Q16832, MIG20a, TYRO10 AND Treatment
6 results:
1. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract] [Full Text] [Related]
2. Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
[TBL] [Abstract] [Full Text] [Related]
3. Targeted therapy in nonsmall cell lung cancer.
Puri T
Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive biomarkers in lung cancer. A review.
Thunnissen E; van der Oord K; den Bakker M
Virchows Arch; 2014 Mar; 464(3):347-58. PubMed ID: 24420742
[TBL] [Abstract] [Full Text] [Related]
5. [Advances of molecular targeted therapy in squamous cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):671-5. PubMed ID: 24345494
[TBL] [Abstract] [Full Text] [Related]
6. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract] [Full Text] [Related]
